Limits...
Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.

Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I - BMC Cancer (2009)

Bottom Line: The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated.The peri- and intralesional combination of IFNs-alpha and -gamma was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients.

View Article: PubMed Central - HTML - PubMed

Affiliation: National Institute of Oncology and Radiobiology, Havana, Cuba. uninor@infomed.sld.cu

ABSTRACT

Background: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery. Interferons (IFN) may provide a non-surgical approach to the management of these tumors. The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).

Methods: Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks. They had been previously treated with surgery and/or radiotherapy or chemotherapy. Thirteen weeks after the end of treatment, the original lesion sites were examined for histological evidence of remaining tumor.

Results: Sixteen elder (median 70 years-old) patients were included. They beared 12 BCC and 4 SCSC ranging from 1.5 to 12.5 cm in the longest dimension. At the end of treatment 47% CR (complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were obtained. None of the patients relapsed during the treatment period. The median duration of the response was 38 months. Only one patient with complete response had relapsed until today. Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated.

Conclusion: The peri- and intralesional combination of IFNs-alpha and -gamma was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients. This is the first report of such treatment in patients with advance non-melanoma skin cancer. The encouraging result justifies further confirmatory trials.

Trial registration: Current Controlled Trials RPCEC00000052.

Show MeSH

Related in: MedlinePlus

Patients with SCSC grade I previously treated with surgery, topic 5-FU and radiotherapy. He presented an extensive tumor lesion in the left ear and external auditory conduit and with indication of ear and external auditory conduit resection and reconstruction. After IFN combination administration a complete clinical response was observed that was sustained for 24 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2724551&req=5

Figure 3: Patients with SCSC grade I previously treated with surgery, topic 5-FU and radiotherapy. He presented an extensive tumor lesion in the left ear and external auditory conduit and with indication of ear and external auditory conduit resection and reconstruction. After IFN combination administration a complete clinical response was observed that was sustained for 24 months.

Mentions: With the IFN combination treatment was achieved an OR in 87% of cases (CR 47% + PR 40%). Most of 12 patients treated only with IFN combination (84%) obtained an OR, with completely disappearance of tumor in 50% of them. The responses in these so difficult to treat cases, even low or partial or the stabilization deserve the attention of international community because they are patients without other treatment options. In the Figures 1, 2, 3, and 4, are depicted some examples with partial and complete responses.


Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.

Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I - BMC Cancer (2009)

Patients with SCSC grade I previously treated with surgery, topic 5-FU and radiotherapy. He presented an extensive tumor lesion in the left ear and external auditory conduit and with indication of ear and external auditory conduit resection and reconstruction. After IFN combination administration a complete clinical response was observed that was sustained for 24 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2724551&req=5

Figure 3: Patients with SCSC grade I previously treated with surgery, topic 5-FU and radiotherapy. He presented an extensive tumor lesion in the left ear and external auditory conduit and with indication of ear and external auditory conduit resection and reconstruction. After IFN combination administration a complete clinical response was observed that was sustained for 24 months.
Mentions: With the IFN combination treatment was achieved an OR in 87% of cases (CR 47% + PR 40%). Most of 12 patients treated only with IFN combination (84%) obtained an OR, with completely disappearance of tumor in 50% of them. The responses in these so difficult to treat cases, even low or partial or the stabilization deserve the attention of international community because they are patients without other treatment options. In the Figures 1, 2, 3, and 4, are depicted some examples with partial and complete responses.

Bottom Line: The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated.The peri- and intralesional combination of IFNs-alpha and -gamma was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients.

View Article: PubMed Central - HTML - PubMed

Affiliation: National Institute of Oncology and Radiobiology, Havana, Cuba. uninor@infomed.sld.cu

ABSTRACT

Background: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery. Interferons (IFN) may provide a non-surgical approach to the management of these tumors. The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).

Methods: Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks. They had been previously treated with surgery and/or radiotherapy or chemotherapy. Thirteen weeks after the end of treatment, the original lesion sites were examined for histological evidence of remaining tumor.

Results: Sixteen elder (median 70 years-old) patients were included. They beared 12 BCC and 4 SCSC ranging from 1.5 to 12.5 cm in the longest dimension. At the end of treatment 47% CR (complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were obtained. None of the patients relapsed during the treatment period. The median duration of the response was 38 months. Only one patient with complete response had relapsed until today. Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated.

Conclusion: The peri- and intralesional combination of IFNs-alpha and -gamma was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients. This is the first report of such treatment in patients with advance non-melanoma skin cancer. The encouraging result justifies further confirmatory trials.

Trial registration: Current Controlled Trials RPCEC00000052.

Show MeSH
Related in: MedlinePlus